Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 0.24% is 103% above its 5-year average of -8.46%, near the high end of its 5-year range (-29.99%–3.19%).
106.90% above its 12-month average of -3.48%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.19%.
EBITDA MARGIN
0.24%
EBITDA MARGIN AVG TTM
-3.48%
EBITDA MARGIN AVG 3Y
-2.58%
EBITDA MARGIN AVG 5Y
-8.46%
EBITDA MARGIN AVG 10Y
-0.22%
EBITDA MARGIN AVG 15Y
2.91%
EBITDA MARGIN AVG 20Y
1.05%
CURRENT VS TTM AVG
+106.90%
CURRENT VS 3Y AVG
+109.30%
CURRENT VS 5Y AVG
+102.84%
CURRENT VS 10Y AVG
+210.37%
CURRENT VS 15Y AVG
-91.76%
CURRENT VS 20Y AVG
-77.10%
NeoGenomics, Inc.
Market Cap
$470.35M
EBITDA Margin
0.24%
TTM Avg
-3.48%
3Y Avg
-2.58%
5Y Avg
-8.46%
Market Cap
$389.98M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$41.24M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$1.71B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.74B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$2.13B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.49B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeoGenomics, Inc. (NEO) | $470.35M | 0.24% | -3.48% | -2.58% | -8.46% |
| NRC Health (NRC)vs › | $459.30M | 21.99% | 25.40% | 28.98% | 31.97% |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | -48.80% | -44.09% | -45.35% | -45.35% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | 3.96% | -13.21% | -146.19% | -104.68% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -628.14% | -766.74% | -948.44% | -801.32% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 16.41% | 1.22% | -1.65% | 4.31% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.13B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | -270.04% | -444.88% | -365.27% | -89273.54% |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 22.42% | 17.70% | -0.76% | -37.34% |
Gross Margin
42.9%
EBITDA Margin
0.2%
Operating Margin
-8.6%
Net Margin
-6.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 3.19% |
| 2026-03-31 | -0.98% |
| 2025-12-31 | 2.76% |
| 2025-09-30 | -5.63% |
| 2025-06-30 | -16.75% |
| 2025-03-31 | -6.01% |
| 2024-12-31 | -0.12% |
| 2024-09-30 | -1.91% |
| 2024-06-30 | -2.33% |
| 2024-03-31 | -7.87% |
| 2023-12-31 | -0.14% |
| 2023-09-30 | -3.99% |
| 2023-06-30 | -7.92% |
| 2023-03-31 | -12.57% |
| 2022-12-31 | -6.00% |
| 2022-09-30 | -17.12% |
| 2022-06-30 | -18.14% |
| 2022-03-31 | -29.99% |
| 2021-12-31 | -19.65% |
| 2021-09-30 | -17.01% |
| 2021-06-30 | -9.58% |
| 2021-03-31 | -3.55% |
| 2020-12-31 | 12.04% |
| 2020-09-30 | 10.89% |
| 2020-06-30 | -12.08% |
| 2020-03-31 | 3.21% |
| 2019-12-31 | 9.27% |
| 2019-09-30 | 10.40% |
| 2019-06-30 | 11.90% |
| 2019-03-31 | 10.86% |
| 2018-12-31 | 11.53% |
| 2018-09-30 | 13.57% |
| 2018-06-30 | 8.89% |
| 2018-03-31 | 11.91% |
| 2017-12-31 | 14.95% |
| 2017-09-30 | 5.20% |
| 2017-06-30 | 11.19% |
| 2017-03-31 | 9.06% |
| 2016-12-31 | 5.41% |
| 2016-09-30 | 12.23% |
| 2016-06-30 | 11.95% |
| 2016-03-31 | 12.62% |
| 2015-12-31 | -12.20% |
| 2015-09-30 | 7.68% |
| 2015-06-30 | 7.34% |
| 2015-03-31 | 4.86% |
| 2014-12-31 | 11.28% |
| 2014-09-30 | 6.69% |
| 2014-06-30 | 9.10% |
| 2014-03-31 | 8.81% |
| 2013-12-31 | 12.73% |
| 2013-09-30 | 13.50% |
| 2013-06-30 | 10.40% |
| 2013-03-31 | 8.63% |
| 2012-12-31 | 8.99% |
| 2012-09-30 | 2.23% |
| 2012-06-30 | 11.22% |
| 2012-03-31 | 10.71% |
| 2011-12-31 | 10.73% |
| 2011-09-30 | 4.97% |
| 2011-06-30 | 3.45% |
| 2011-03-31 | -2.53% |
| 2010-12-31 | -0.90% |
| 2010-09-30 | -6.35% |
| 2010-06-30 | -4.41% |
| 2010-03-31 | -2.09% |
| 2009-12-31 | -13.05% |
| 2009-09-30 | -4.32% |
| 2009-06-30 | 5.42% |
| 2009-03-31 | 5.57% |
| 2008-12-31 | -8.71% |
| 2008-09-30 | 2.33% |
| 2008-06-30 | 6.33% |
| 2008-05-13 | -1.29% |
| 2007-12-31 | -37.52% |
| 2007-09-30 | -17.48% |
| 2007-06-30 | -26.93% |
| 2007-05-11 | -5.91% |
| 2006-12-31 | -16.92% |
| 2006-09-30 | 12.58% |
| 2006-06-30 | 17.70% |
| 2006-03-31 | 17.18% |
| 2005-12-31 | -36.56% |
| 2005-09-30 | -16.16% |
| 2005-06-30 | -26.97% |
| 2005-03-31 | -69.95% |
| 2004-12-31 | -182.33% |
| 2004-09-30 | -100.93% |
| 2004-06-30 | -98.98% |
| 2004-03-31 | -74.81% |
| 2003-12-31 | -85.53% |
| 2003-09-30 | -124.79% |
| 2003-06-30 | -161.39% |
| 2003-03-31 | -140.62% |
| 2002-09-30 | -801.23% |
